JERUSALEM and LUND, SWEDEN and SEATTLE, WA--(Marketwire - April 29, 2009) - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from several new clinical and preclinical studies providing further insight on the immunomodulatory mechanism of action (MOA) of laquinimod, a novel oral once-daily compound being developed for the treatment of relapsing-remitting multiple sclerosis (RRMS). Four sets of data being presented at the 61st Annual American Academy of Neurology Meeting (AAN) in Seattle stand to increase the understanding of how laquinimod may reduce multiple sclerosis activity and affect mechanisms related to disease pathology.
Contact:
Elana Holzman
Teva Pharmaceutical Industries Ltd.
+972-(3)-926-7554
Kevin Mannix
Teva North America
+1-(215)-591-8912
Contact:
Tomas Leanderson
Active Biotech AB
+46-46-19-20-95
Göran Forsberg
Active Biotech AB
+46-46-19-11-54